Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haematopoietic progenitor cell transplantation.

Trial Profile

Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haematopoietic progenitor cell transplantation.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Thiotepa (Primary)
  • Indications Haematological disorders
  • Focus Pharmacokinetics
  • Sponsors ADIENNE
  • Most Recent Events

    • 26 Mar 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
    • 13 Mar 2015 Planned number of patients changed from 1 to 30.
    • 11 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top